What's Happening?
Apreo Health, a medical device company, has closed a $130 million Series B financing round to advance its BREATHE-3 trial and early commercialization of its airway scaffold for severe emphysema. The financing was led by Bain Capital Life Sciences and Norwest, with participation from other investors. The funds will support a multicenter trial to evaluate the safety and efficacy of the BREATHE Airway Scaffold, a device designed to relieve lung hyperinflation in emphysema patients. The financing will also aid regulatory activities and market potential demonstration.
AD
Why It's Important?
The development of the BREATHE Airway Scaffold addresses a significant unmet need in the treatment of severe emphysema, a condition affecting millions in the U.S. Despite its prevalence, fewer than 1% of patients receive interventional treatment. Apreo Health's novel approach could redefine emphysema care, offering a non-destructive, tissue-sparing solution. This advancement has the potential to improve the quality of life for many patients and transform the treatment landscape for COPD-related conditions.
What's Next?
Apreo Health plans to complete the pivotal BREATHE-3 trial and advance towards expanded access for patients. The company aims to demonstrate the scaffold's market potential and secure regulatory approvals. Stakeholders, including healthcare providers and patients, may anticipate broader adoption of this innovative treatment, potentially influencing future emphysema care standards.
